Table 4.
The biochemical results of the analysis of variance for the two-period cross-over design.
| Source Parameter |
Effect of Treatment (F, p-value) | Effect of Treatment Sequence (F, p-value) | Effect of Sequence (F, p-value) |
|---|---|---|---|
| FBS | 0.11 (0.749) | 0.20 (0.659) | 3.11 (0.100) |
| HCT | 1.08 (0.318) | 0.14 (0.712) | 6.97 (0.020*) |
| Hgb | 0.39 (0.541) | 0.45 (0.513) | 2.50 (0.138) |
| PLT | 0.58 (0.459) | 0.36 (0.560) | 0.05 (0.818) |
| WBC | 0.69 (0.690) | 0.005 (0.944) | 9.59 (0.008*) |
| TG | 0.17 (0.688) | 0.08 (0.784) | 0.07 (0.791) |
| Chol | 0.02 (0.877) | 0.47 (0.504) | 0.47 (0.305) |
| HDL | 0.59 (0.454) | 0.09 (0.769) | 0.008 (0.930) |
| ALP | 0.001 (0.971) | 0.16 (0.692) | 0.11 (0.739) |
| GGT | 2.65 (0.126) | 0.75 (0.400) | 0.09 (0.760) |
| OT | 0.05 (0.823) | 1.86 (0.194) | 0.01 (0.905) |
| Pt | 0.24 (0.630) | 0.02 (0.890) | 0.001 (0.977) |
| Cr | 0.76 (0.396) | 0.77 (0.393) | 0.77 (0.394) |
| Alb | 1.69 (0.215) | 4.56 (0.051) | 0.72 (0.409) |
| NO | 4.98 (0.042*) | 0.43 (0.524) | 1.92 (0.187) |
| MDA | 2.65 (0.126) | 0.27 (0.610) | 0.04 (0.847) |
| TAC | 0.01 (0.934) | 0.19 (0.689) | 0.18 (0.677) |
* P < 0.05 (statistically significant).
FBS: Fasting Blood Sugar; HCT: Hematocrit; Hgb: Hemoglobin; PLT: Platelet; WBC: White Blood Cell; TG: Triglyceride; CHOL: Cholesterol; HDL: High-Density Lipoprotein; ALP: Alkaline Phosphatase; GGT: Gamma-Glutamyl Transferase; OT: Serum Glutamic Oxaloacetic Transaminase; PT: Serum Glutamate Pyruvate Transaminase; Cr: Creatinine; Alb: Albumin; NO: Nitric Oxide; MDA: Malondialdehyde; TAC: Total Antioxidant Capacity.